pBabe-Kras Wt Citations (14)
Originally described in: Mutant Ras ConstructsUnpublished
Articles Citing pBabe-Kras Wt
| Articles |
|---|
| Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, Kleinschmidt-DeMasters BK, Fitzwalter BE, Goodall ML, Thorburn J, Amani V, Donson AM, Birks DK, Mirsky DM, Hankinson TC, Handler MH, Green AL, Vibhakar R, Foreman NK, Thorburn A. Elife. 2017 Jan 17;6:e19671. doi: 10.7554/eLife.19671. PubMed |
| Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Zeng M, Lu J, Li L, Feru F, Quan C, Gero TW, Ficarro SB, Xiong Y, Ambrogio C, Paranal RM, Catalano M, Shao J, Wong KK, Marto JA, Fischer ES, Janne PA, Scott DA, Westover KD, Gray NS. Cell Chem Biol. 2017 Aug 17;24(8):1005-1016.e3. doi: 10.1016/j.chembiol.2017.06.017. Epub 2017 Aug 3. PubMed |
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C, Kohler J, Zhou ZW, Wang H, Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R, Santamaria D, Westover KD, Janne PA.
Cell. 2018 Feb 8;172(4):857-868.e15. doi: 10.1016/j.cell.2017.12.020. Epub 2018 Jan 11.
PubMed
Associated Plasmids |
| Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS(G12C)-Driven Mouse Model of Lung Cancer. Li S, Liu S, Deng J, Akbay EA, Hai J, Ambrogio C, Zhang L, Zhou F, Jenkins RW, Adeegbe DO, Gao P, Wang X, Paweletz CP, Herter-Sprie GS, Chen T, Gutierrez-Quiceno L, Zhang Y, Merlino AA, Quinn MM, Zeng Y, Yu X, Liu Y, Fan L, Aguirre AJ, Barbie DA, Yi X, Wong KK. Clin Cancer Res. 2018 Oct 1;24(19):4854-4864. doi: 10.1158/1078-0432.CCR-17-3438. Epub 2018 Jun 26. PubMed |
| Phenotypic Switching of Naive T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, Nathan A, Mambetsariev I, Poroyko V, Gao H, Chu P, Sattler M, Bild A, Manuel ER, Lee PP, Jolly MK, Kulkarni P, Salgia R. J Clin Med. 2019 Oct 18;8(10). pii: jcm8101726. doi: 10.3390/jcm8101726. PubMed |
| Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, Kojima S, Takeyama R, Hashimoto T, Kiyono T, Ikemura M, Taguchi A, Tanaka T, Tanaka Y, Sakata S, Takeuchi K, Muraoka A, Osuka S, Saito T, Oda K, Osuga Y, Terao Y, Kawazu M, Mano H. Nat Commun. 2019 Dec 19;10(1):5785. doi: 10.1038/s41467-019-13708-y. PubMed |
| KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Zhou ZW, Ambrogio C, Bera AK, Li Q, Li XX, Li L, Son J, Gondi S, Li J, Campbell E, Jin H, Okoro JJ, Xu CX, Janne PA, Westover KD. Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-20-0448. doi: 10.1158/0008-5472.CAN-20-0448. PubMed |
| Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Li R, Ng TSC, Wang SJ, Prytyskach M, Rodell CB, Mikula H, Kohler RH, Garlin MA, Lauffenburger DA, Parangi S, Dinulescu DM, Bardeesy N, Weissleder R, Miller MA. Nat Nanotechnol. 2021 Jul;16(7):830-839. doi: 10.1038/s41565-021-00897-1. Epub 2021 May 6. PubMed |
| A structural model of a Ras-Raf signalosome. Mysore VP, Zhou ZW, Ambrogio C, Li L, Kapp JN, Lu C, Wang Q, Tucker MR, Okoro JJ, Nagy-Davidescu G, Bai X, Pluckthun A, Janne PA, Westover KD, Shan Y, Shaw DE. Nat Struct Mol Biol. 2021 Oct;28(10):847-857. doi: 10.1038/s41594-021-00667-6. Epub 2021 Oct 8. PubMed |
| Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, Tandon V. Free Radic Biol Med. 2021 Dec;177:299-312. doi: 10.1016/j.freeradbiomed.2021.11.001. Epub 2021 Nov 3. PubMed |
| Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. Ricciuti B, Son J, Okoro JJ, Mira A, Patrucco E, Eum Y, Wang X, Paranal R, Wang H, Lin M, Haikala HM, Li J, Xu Y, Alessi JV, Chhoeu C, Redig AJ, Kohler J, Dholakia KH, Chen Y, Richard E, Nokin MJ, Santamaria D, Gokhale PC, Awad MM, Janne PA, Ambrogio C. Clin Cancer Res. 2022 Apr 14;28(8):1640-1650. doi: 10.1158/1078-0432.CCR-21-2719. PubMed |
| The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer. Entrialgo-Cadierno R, Cueto-Urena C, Welch C, Feliu I, Macaya I, Vera L, Morales X, Michelina SV, Scaparone P, Lopez I, Darbo E, Erice O, Vallejo A, Moreno H, Goni-Salaverri A, Lara-Astiaso D, Halberg N, Cortes-Dominguez I, Guruceaga E, Ambrogio C, Lecanda F, Vicent S. Mol Cancer. 2023 May 20;22(1):86. doi: 10.1186/s12943-023-01788-w. PubMed |
| Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Shin DH, Jo JY, Choi M, Kim KH, Bae YK, Kim SS. Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2. PubMed |
| Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. Gong Z, Xue L, Vlantis AC, van Hasselt CA, Chan JYK, Fang J, Wang R, Yang Y, Li D, Zeng X, Tong MCF, Chen GG. J Endocrinol Invest. 2023 Dec 7. doi: 10.1007/s40618-023-02248-4. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.